Admittedly, I've only come across this stock, but everything I've read points to it being a buy. In their most recent earnings call, they said they expect $800-820 million in revenue over next year and $100-150 million in net income, compared to $730 million in revenue last year, and a loss of $21 million for income.
This would calculate to be a $1.3 -1.5 EPS, yet shares are going for only $15. That puts their forward PE ratio at ~10, which seems incredibly low, considering that they've been growing their international business insanely quick. They nearly doubled their business in India, APAC and Latin America, which seems to imply that their reputation has been growing quickly in these areas as a trustable screening service.
Leave a Reply